Vieira Roberto Wandenkolk
Known title: President, OncologyCIK: 0002150104
Associated companies
Transaction History
| CORT | ▲ Buy | Option Exercise | 8,333 | $180K | 10/2/2026 | View on chart |
| CORT | ▼ Sell | Open Market | 1,100 | $126K | 10/2/2026 | View on chart |
| CORT | ▼ Sell | Open Market | 2,086 | $241K | 10/2/2026 | View on chart |
| CORT | ▼ Sell | Open Market | 5,147 | $600K | 10/2/2026 | View on chart |
| CORT | ▼ Sell | Open Market | 296 | $30K | 9/16/2026 | View on chart |
| CORT | ▼ Sell | Tax Withholding | 102 | $12K | 9/2/2026 | View on chart |
| CORT | ▼ Sell | Open Market | 23,600 | $2.6M | 9/2/2026 | View on chart |
| CORT | ▲ Buy | Option Exercise | 58,333 | $1.3M | 9/2/2026 | View on chart |
| CORT | ▼ Sell | Open Market | 23,770 | $2.6M | 9/2/2026 | View on chart |
| CORT | ▼ Sell | Open Market | 1,537 | $171K | 9/2/2026 | View on chart |
| CORT | ▼ Sell | Open Market | 1,606 | $183K | 9/2/2026 | View on chart |
| CORT | ▼ Sell | Open Market | 974 | $109K | 9/2/2026 | View on chart |
| CORT | ▼ Sell | Open Market | 5,621 | $644K | 9/2/2026 | View on chart |
| CORT | ▼ Sell | Open Market | 1,225 | $141K | 9/2/2026 | View on chart |
| CORT | ▲ Buy | Grant | 138 | $0 | 9/1/2026 | View on chart |
| CORT | ▲ Buy | Grant | 138 | $16K | 9/1/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
CORT Featured in Low-Beta Healthcare Stock List
Corcept Therapeutics was included in a recent list of low-beta healthcare stocks, highlighting its potential stability amid market concerns about interest rates. The company currently trades within its 52-week range, with a high trailing P/E ratio of 227.7. Analysts maintain an average price target of $141.00, reflecting a wide range of expectations for the stock's future performance.
CORT Featured in Low-Beta Healthcare Stock List. Corcept Therapeutics was included in a recent list of low-beta healthcare stocks, highlighting its potential stability amid market concerns about interest rates. The company currently trades within its 52-week range, with a high trailing P/E ratio of 227.7. Analysts maintain an average price target of $141.00, reflecting a wide range of expectations for the stock's future performance.